Wells Fargo & Company Aldeyra Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
A detailed history of Wells Fargo & Company transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 387,304 shares of ALDX stock, worth $1.28 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
387,304
Previous 345,113
12.23%
Holding current value
$1.28 Million
Previous $1.21 Million
4.54%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding ALDX
# of Institutions
106Shares Held
35.4MCall Options Held
104KPut Options Held
88.1K-
Perceptive Advisors LLC New York, NY8.59MShares$28.4 Million0.59% of portfolio
-
Knoll Capital Management, LLC Miami, FL5.48MShares$18.1 Million11.18% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.87MShares$12.8 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.31MShares$11 Million0.0% of portfolio
-
Kennedy Capital Management, Inc. St Louis, MO1.32MShares$4.36 Million0.09% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $193M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...